
|Peer-Reviewed|December 24, 2020
- February 2021
- Volume 27
- Issue 2
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Advertisement
Articles in this issue
over 4 years ago
Radiation Oncology’s Role in the Next Chapter of Payment Reformover 4 years ago
Flying the Plane While You Build Itover 4 years ago
The Untapped Potential of Cell and Gene Therapyover 4 years ago
Possible Treatment Identified for Aggressive NSCLC SubsetNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
4
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
5















































